Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Get Free Report) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 33,800 shares, an increase of 15.4% from the August 15th total of 29,300 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average daily trading volume, of 961,300 shares, the days-to-cover ratio is currently 0.0 days.
Hedge Funds Weigh In On Eloxx Pharmaceuticals
An institutional investor recently raised its position in Eloxx Pharmaceuticals stock. Bank of America Corp DE lifted its position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Free Report) by 238.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,213 shares of the company’s stock after acquiring an additional 40,990 shares during the quarter. Bank of America Corp DE owned approximately 0.07% of Eloxx Pharmaceuticals worth $32,000 at the end of the most recent reporting period. 8.64% of the stock is owned by institutional investors.
Eloxx Pharmaceuticals Trading Up 1.6 %
ELOX stock traded up $0.09 during trading on Tuesday, reaching $5.55. 20,836 shares of the stock were exchanged, compared to its average volume of 564,148. The firm’s 50 day moving average is $5.89 and its 200 day moving average is $5.60. The firm has a market cap of $15.26 million, a P/E ratio of -0.48 and a beta of 2.66. Eloxx Pharmaceuticals has a twelve month low of $1.70 and a twelve month high of $10.90.
Wall Street Analysts Forecast Growth
Separately, Oppenheimer lifted their price target on shares of Eloxx Pharmaceuticals from $50.00 to $55.00 in a research note on Tuesday, July 11th.
Eloxx Pharmaceuticals Company Profile
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
- Five stocks we like better than Eloxx Pharmaceuticals
- What Are Meme Stocks and Are They Viable Investments?
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How is Compound Interest Calculated?
- Virtual Riches: 3 Stocks Leading the VR Revolution
- Insider Trades May Not Tell You What You Think
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.